LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Status:
Terminated
Trial end date:
2019-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the disease control rate of nintedanib in subjects
with metastatic appendiceal cancer for whom initial fluoropyrimidine-based chemotherapy has
failed. Based on previous studies, the anticancer activity of nintedanib in lung and ovarian
cancer trials, along with the similarities between appendiceal and colorectal cancer and
potentially ovarian cancer, warrant additional investigation for the optimal treatment of
metastatic appendiceal carcinomas.